or Try an Advanced Search...

    Technical Analysis for ABVX - ABIVAX Société Anonyme

    Grade Last Price % Change Price Change
    D 10.49 -1.04% -0.11
    ABVX closed down 1.04 percent on Wednesday, October 30, 2024, on 14 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    Earnings due: Nov 7
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Flat
    Historical ABVX trend table...
    Date Alert Name Type % Chg
    Weak + Overbought Other 0.00%
    Overbought Stochastic Strength 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.04%
    Weak + Overbought Other -1.04%
    Overbought Stochastic Strength -1.04%
    Stochastic Reached Overbought Strength -1.87%
    Weak + Overbought Other -1.87%
    Outside Day Range Expansion -1.87%
    Overbought Stochastic Strength -1.87%
    Stochastic Sell Signal Bearish 1.84%
    Older End-of-Day Signals for ABVX ...

       Recent Intraday Alerts

    Alert Time
    Possible Inside Day about 13 hours ago
    Down 1% about 18 hours ago
    Up 1% about 18 hours ago
    60 Minute Opening Range Breakdown 1 day ago
    Down 2 % 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ABVX Chart by TradingView
    Basic chart:

    Profile

    ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Autoimmune Disease Inflammatory Bowel Disease Ulcerative Colitis Gastroenterology Colitis Diarrhea

    Is ABVX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 3 Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
    Oct 3 Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
    Sep 9 Abivax reports 1H results
    Sep 9 Abivax presents first-half 2024 financial results
    Aug 6 Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
    Jul 15 Abivax Provides Operational and Key Program Update
    Jun 4 Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
    See more ABVX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 17.02
    52 Week Low 8.75
    Average Volume 122,583
    200-Day Moving Average 12.82
    50-Day Moving Average 11.01
    20-Day Moving Average 10.01
    10-Day Moving Average 10.46
    Average True Range 0.47
    RSI (14) 50.25
    ADX 20.1
    +DI 24.52
    -DI 17.18
    Chandelier Exit (Long, 3 ATRs) 9.95
    Chandelier Exit (Short, 3 ATRs) 10.17
    Upper Bollinger Bands 11.08
    Lower Bollinger Band 8.95
    Percent B (%b) 0.72
    BandWidth 21.29
    MACD Line -0.09
    MACD Signal Line -0.22
    MACD Histogram 0.131
    Fundamentals Value
    Market Cap 660 Million
    Num Shares 62.9 Million
    EPS -2.66
    Price-to-Earnings (P/E) Ratio -3.94
    Price-to-Sales 35265.26
    Price-to-Book 8.00
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 10.96
    Resistance 3 (R3) 10.99 10.87 10.88
    Resistance 2 (R2) 10.87 10.75 10.85 10.85
    Resistance 1 (R1) 10.68 10.68 10.65 10.65 10.83
    Pivot Point 10.56 10.56 10.54 10.54 10.56
    Support 1 (S1) 10.37 10.44 10.34 10.34 10.15
    Support 2 (S2) 10.25 10.37 10.23 10.13
    Support 3 (S3) 10.06 10.25 10.10
    Support 4 (S4) 10.03